These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35636705)

  • 1. Sustained DMARD-free remission in rheumatoid arthritis - about concepts and moving towards practice.
    Verstappen M; van der Helm-van Mil AHM
    Joint Bone Spine; 2022 Nov; 89(6):105418. PubMed ID: 35636705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.
    Verstappen M; van Steenbergen HW; de Jong PHP; van der Helm-van Mil AHM
    Arthritis Res Ther; 2022 Jan; 24(1):4. PubMed ID: 34980246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis.
    Verstappen M; Niemantsverdriet E; Matthijssen XME; le Cessie S; van der Helm-van Mil AHM
    Arthritis Res Ther; 2020 Nov; 22(1):276. PubMed ID: 33228814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation.
    Verstappen M; Matthijssen XME; Connolly SE; Maldonado MA; Huizinga TWJ; van der Helm-van Mil AHM
    Rheumatology (Oxford); 2022 Dec; 62(1):124-134. PubMed ID: 35583256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation.
    Boeters DM; Burgers LE; Sasso EH; Huizinga TWJ; van der Helm-van Mil AHM
    Arthritis Res Ther; 2019 May; 21(1):121. PubMed ID: 31088574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.
    Teitsma XM; Jacobs JWG; Mokry M; Borm MEA; Pethö-Schramm A; van Laar JM; Bijlsma JWJ; Lafeber FPJ
    Arthritis Res Ther; 2017 Jul; 19(1):170. PubMed ID: 28728565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study.
    Burgers LE; Boeters DM; Reijnierse M; van der Helm-van Mil AHM
    Arthritis Res Ther; 2018 Apr; 20(1):68. PubMed ID: 29636084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
    Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
    Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
    Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands.
    Matthijssen XME; Niemantsverdriet E; Huizinga TWJ; van der Helm-van Mil AHM
    PLoS Med; 2020 Sep; 17(9):e1003296. PubMed ID: 32960885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
    Bergstra SA; Van Der Pol JA; Riyazi N; Goekoop-Ruiterman YPM; Kerstens PJSM; Lems W; Huizinga TWJ; Allaart CF
    RMD Open; 2020 May; 6(1):. PubMed ID: 32471854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care.
    Burgers LE; van der Pol JA; Huizinga TWJ; Allaart CF; van der Helm-van Mil AHM
    Arthritis Res Ther; 2019 May; 21(1):115. PubMed ID: 31064384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.
    Akdemir G; Heimans L; Bergstra SA; Goekoop RJ; van Oosterhout M; van Groenendael JHLM; Peeters AJ; Steup-Beekman GM; Lard LR; de Sonnaville PBJ; Grillet BAM; Huizinga TWJ; Allaart CF
    Ann Rheum Dis; 2018 Jan; 77(1):111-118. PubMed ID: 28970207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.
    Teitsma XM; Yang W; Jacobs JWG; Pethö-Schramm A; Borm MEA; Harms AC; Hankemeier T; van Laar JM; Bijlsma JWJ; Lafeber FPJG
    Arthritis Res Ther; 2018 Oct; 20(1):230. PubMed ID: 30322408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort.
    Verstappen M; Matthijssen XME; van der Helm-van Mil AHM
    Rheumatology (Oxford); 2022 Aug; 61(8):3212-3222. PubMed ID: 34850952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.
    Teitsma XM; Jacobs JWG; Concepcion AN; Pethö-Schramm A; Borm MEA; van Laar JM; Bijlsma JWJ; Lafeber FPJG
    Clin Exp Rheumatol; 2018; 36(6):976-983. PubMed ID: 29745885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott IC; Kingsley GH; Scott DL
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S4-8. PubMed ID: 24129128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.